New forms of treatment for inflammatory bowel disease.
作者信息
Rachmilewitz D
机构信息
Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
出版信息
Gut. 1992 Oct;33(10):1301-2. doi: 10.1136/gut.33.10.1301.
Abstract
摘要
相似文献
1
New forms of treatment for inflammatory bowel disease.炎症性肠病的新型治疗方法。
Gut. 1992 Oct;33(10):1301-2. doi: 10.1136/gut.33.10.1301.
2
Drugs for inflammatory bowel disease.用于炎症性肠病的药物。
Treat Guidel Med Lett. 2012 Mar;10(115):19-28.
3
[Changing treatment of inflammatory bowel diseases].[炎症性肠病治疗的变革]
Duodecim. 1994;110(20):1945-54.
4
[Chronic inflammatory bowel diseases. Immunosuppressive drug saves on corticoids].
MMW Fortschr Med. 1999 Sep 23;141(38):55.
5
[Inflammatory bowel diseases: conservative therapy].[炎症性肠病：保守治疗]
Ther Umsch. 1991 Jul;48(7):464-70.
6
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.用于治疗炎症性肠病的5-脂氧合酶抑制剂。
Agents Actions. 1992;Spec No:C37-46.
7
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.皮质类固醇和免疫抑制药物在炎症性肠病中的应用：意大利炎症性肠病研究小组临床实践指南
Dig Liver Dis. 2017 Jun;49(6):604-617. doi: 10.1016/j.dld.2017.01.161. Epub 2017 Jan 25.
8
1989 Henry Baker lecture. Inflammatory bowel disease: back to the future.1989年亨利·贝克讲座。炎症性肠病：回归未来。
Am J Gastroenterol. 1990 Apr;85(4):373-6.
9
Inflammatory bowel disease.炎症性肠病
CMAJ. 1989 Jul 15;141(2):113-23; discussion 123-4.
10
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.用于治疗炎症性肠病的药物的风险效益评估。
Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005.
引用本文的文献
1
Future therapeutic approaches for inflammatory bowel diseases.炎症性肠病的未来治疗方法。
Gastroenterology. 2011 May;140(6):1838-46. doi: 10.1053/j.gastro.2011.02.014.
2
A modest proposal for future trials of medical treatment in inflammatory bowel disease.关于炎症性肠病未来医学治疗试验的适度提议。
Gut. 1994 Jun;35(6):860. doi: 10.1136/gut.35.6.860.
本文引用的文献
1
A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
Scand J Gastroenterol. 1987 Oct;22(8):987-92. doi: 10.3109/00365528708991947.
2
Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.用4-氨基水杨酸灌肠剂治疗左侧溃疡性结肠炎。一项双盲、安慰剂对照试验。
Ann Intern Med. 1988 Feb;108(2):195-9. doi: 10.7326/0003-4819-108-2-195.
3
Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis.
Can J Physiol Pharmacol. 1988 Apr;66(4):422-5. doi: 10.1139/y88-071.
4
4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl.与5-氨基水杨酸不同，4-氨基水杨酸对人中性粒细胞中的花生四烯酸代谢或自由基1,1-二苯基-2-苦基肼没有影响。
Pharmacol Toxicol. 1988 Apr;62(4):223-6. doi: 10.1111/j.1600-0773.1988.tb01876.x.
5
Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.血小板活化因子在溃疡性结肠炎中的作用。活动期疾病期间产生增加，柳氮磺胺吡啶和泼尼松龙可抑制其产生。
Gastroenterology. 1988 Nov;95(5):1167-72. doi: 10.1016/0016-5085(88)90346-0.
6
A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.
N Engl J Med. 1989 Sep 28;321(13):845-50. doi: 10.1056/NEJM198909283211301.
7
Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.甲氨蝶呤可使难治性炎症性肠病患者实现临床和组织学缓解。
Ann Intern Med. 1989 Mar 1;110(5):353-6. doi: 10.7326/0003-4819-110-5-353.
8
Fluticasone propionate in Crohn's disease.丙酸氟替卡松用于克罗恩病
Gut. 1991 Jun;32(6):657-61. doi: 10.1136/gut.32.6.657.
9
Preliminary report: cyclosporin in treatment of severe active ulcerative colitis.
Lancet. 1990 Jul 7;336(8706):16-9. doi: 10.1016/0140-6736(90)91521-b.
Zotero 插件